Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia

Ann Pharmacother. 1995 Dec;29(12):1197-201. doi: 10.1177/106002809502901201.

Abstract

Objective: To evaluate the usefulness of a 20% lipid emulsion as a delivery system for amphotericin B (1 mg/mL) administered over 1 hour to patients with neutropenia with hematologic malignancies compared with amphotericin B (0.1 mg/mL) administered in dextrose 5% solution over the same time.

Design: A prospective, comparative, randomized, labeled study.

Setting: Hematology unit, pharmacy service, university general hospital.

Participants: Twenty patients with neutropenia with hematologic malignancies and proven or suspected fungal infections, 10 in the fat emulsion group (group 1) and 10 in the dextrose 5% group (group 2).

Main outcome measures: Clinical tolerance (i.e., fever, shaking chills, nausea, blood pressure, pulse rate) and biologic tolerance (i.e., urea, creatinine, sodium, potassium).

Results: Clinical tolerance was comparable in both groups although amphotericin B in fat emulsion was better tolerated. Medication for symptoms related to the administration of amphotericin B was given in 6 cases in group 1 and in 8 cases in group 2. There was a statistically significant difference in the urea concentrations between the 2 groups (p = 0.023); there was an observed increase between the initial and the final serum urea (56.8 mg/d in group 1, 79.8 mg/dL in group 2). Statistically significant differences in creatinine serum concentrations (84.9 mumol/L in group 1, 123.8 mumol/L in group 2) (p = 0.047) were found. No differences were found in the antifungal efficacy of the treatment. However, as amphotericin B was started in the majority of cases (75%) as empiric treatment for fever unresponsive to antibiotic therapy, it is difficult to compare the efficacy of both preparations.

Conclusions: The clinical tolerance of lipid-emulsion infusions is similar to that of conventionally administered amphotericin B therapy. Renal toxicity appears to be decreased when the drug is administered in a fat emulsion. This type of preparation permits the reduction of the volume and the time of administration for amphotericin B therapy.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Amphotericin B / administration & dosage*
  • Amphotericin B / therapeutic use
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / adverse effects
  • Antifungal Agents / therapeutic use
  • Fat Emulsions, Intravenous / administration & dosage*
  • Fat Emulsions, Intravenous / therapeutic use
  • Female
  • Glucose / administration & dosage*
  • Glucose / adverse effects
  • Hematologic Diseases / complications*
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Mycoses / complications
  • Mycoses / drug therapy
  • Neutropenia / drug therapy*
  • Neutropenia / etiology
  • Prospective Studies
  • Solutions

Substances

  • Antifungal Agents
  • Fat Emulsions, Intravenous
  • Solutions
  • Amphotericin B
  • Glucose